DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Landmark 2023 cardiovascular outcomes study showing semaglutide (Wegovy) cut major cardiovascular events by 20% in adults with prior heart disease.
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults with established CV disease and overweight or obesity, without diabetes. Over a median 39.8 months, semaglutide 2.4 mg reduced MACE (CV death, non-fatal MI, non-fatal stroke) by 20% vs placebo (HR 0.80). First weight-loss drug with established CV benefit in non-diabetic patients. NEJM 2023.